Incyte (INCY)
102.42
+1.18 (1.17%)
Upcoming Events
Latest Headlines
Form 144 INCYTE CORP Filed by: Tray Thomas
June 4, 2026 4:04 PM - SEC Filing
Mirum and Incyte to present zilurgisertib study results at ENDO 2026
June 4, 2026 8:06 AM - StreetInsider
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
June 4, 2026 8:05 AM - BizWire
Form 4 INCYTE CORP For: Jun 01 Filed by: CAGNONI PABLO J
June 3, 2026 4:58 PM - SEC Filing
Incyte (INCY) Reiterated at Market Perform by Citizens Amid Positive Trial Results
June 2, 2026 4:37 AM - StreetInsider
Incyte (INCY) Reiterated at Buy by Stifel
June 1, 2026 7:34 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
June 1, 2026 6:56 AM - StreetInsider
Incyte drug combination reduces lymphoma progression risk by 25%
June 1, 2026 2:53 AM - StreetInsider
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in P
May 30, 2026 8:00 AM - BizWire
Form 4 INCYTE CORP For: May 26 Filed by: Tray Thomas
May 28, 2026 4:47 PM - SEC Filing
Form 4 INCYTE CORP For: May 26 Filed by: BIENAIME JEAN JACQUES
May 28, 2026 4:46 PM - SEC Filing
JPMorgan says large-cap biotech is back as profits and pipelines fuel upside
May 28, 2026 4:07 PM - StreetInsider
Form DEFA14A INCYTE CORP
May 27, 2026 1:05 PM - SEC Filing
Form 144 INCYTE CORP Filed by: Tray Thomas
May 26, 2026 4:11 PM - SEC Filing
Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
May 26, 2026 8:00 AM - BizWire
Bernstein SocGen Group Starts Incyte (INCY) at Market Perform
May 21, 2026 4:24 PM - StreetInsider
Form 4 INCYTE CORP For: May 19 Filed by: Clancy Paul J
May 21, 2026 4:02 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
May 21, 2026 6:38 AM - StreetInsider
Form 4/A INCYTE CORP For: May 06 Filed by: Stein Steven H
May 20, 2026 4:02 PM - SEC Filing
Form 4/A INCYTE CORP For: May 06 Filed by: CAGNONI PABLO J
May 20, 2026 4:02 PM - SEC Filing
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery
May 20, 2026 8:00 AM - BizWire
JPMorgan Reinstates Incyte (INCY) at Neutral
May 20, 2026 4:30 AM - StreetInsider
Form 144 INCYTE CORP Filed by: Clancy Paul J
May 19, 2026 4:21 PM - SEC Filing
Incyte partners with Edison Scientific to deploy AI platform for drug research
May 19, 2026 8:00 AM - StreetInsider
Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development
May 19, 2026 8:00 AM - BizWire
Form SCHEDULE 13G/A INCYTE CORP Filed by: DODGE & COX
May 14, 2026 12:47 PM - SEC Filing
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress
May 12, 2026 9:30 AM - BizWire
Form SCHEDULE 13D/A INCYTE CORP Filed by: BAKER BROS. ADVISORS LP
May 11, 2026 5:00 PM - SEC Filing
Form 4 INCYTE CORP For: May 08 Filed by: Baker Brothers Life Sciences LP
May 11, 2026 4:46 PM - SEC Filing
Incyte reports 24-week data for Opzelura cream in moderate atopic dermatitis
May 7, 2026 8:50 AM - StreetInsider
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis
May 7, 2026 8:50 AM - BizWire
Form 4 INCYTE CORP For: May 04 Filed by: Upadhyay Suketu
May 6, 2026 4:35 PM - SEC Filing
Form 3 INCYTE CORP For: May 04 Filed by: Upadhyay Suketu
May 6, 2026 4:34 PM - SEC Filing
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 6, 2026 4:30 PM - BizWire
New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1]
May 3, 2026 12:00 PM - PR NewsWire
FDA approves Incyte's once-daily Jakafi XR for blood disorders
May 1, 2026 5:28 PM - StreetInsider
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease
May 1, 2026 5:28 PM - BizWire
Form SCHEDULE 13G INCYTE CORP Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 30, 2026 10:30 AM - SEC Filing
Incyte (INCY) PT Raised to $103 at UBS
April 30, 2026 8:59 AM - StreetInsider
Incyte (INCY) PT Raised to $123 at Stifel Following 'Solid' Q1 Results
April 29, 2026 9:23 AM - StreetInsider
Incyte to Present at Upcoming Investor Conferences
April 29, 2026 8:00 AM - BizWire
H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
April 29, 2026 7:15 AM - StreetInsider
Incyte (INCY) PT Raised to $90 at Oppenheimer
April 28, 2026 4:32 PM - StreetInsider
Form ARS INCYTE CORP For: Dec 31
April 28, 2026 4:27 PM - SEC Filing
Form DEFA14A INCYTE CORP
April 28, 2026 4:27 PM - SEC Filing
Form DEF 14A INCYTE CORP For: Dec 31
April 28, 2026 4:27 PM - SEC Filing
Form 10-Q INCYTE CORP For: Mar 31
April 28, 2026 4:03 PM - SEC Filing
Incyte (INCY) PT Raised to $103 at Morgan Stanley
April 28, 2026 3:10 PM - StreetInsider
Incyte (INCY) PT Raised to $124 at TD Cowen
April 28, 2026 2:52 PM - StreetInsider
Incyte (INCY) Tops Q1 EPS by 46c; offers guidance
April 28, 2026 7:06 AM - StreetInsider
Form 8-K INCYTE CORP For: Apr 28
April 28, 2026 7:03 AM - SEC Filing
Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates
April 28, 2026 7:00 AM - BizWire
Incyte names Suketu Upadhyay as chief financial officer
April 28, 2026 7:00 AM - StreetInsider
Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer
April 28, 2026 7:00 AM - BizWire
MINJUVI approved in Australia for relapsed follicular lymphoma treatment
April 23, 2026 5:48 AM - StreetInsider
MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia
April 23, 2026 3:00 AM - PR NewsWire
Form 4 INCYTE CORP For: Apr 17 Filed by: CAGNONI PABLO J
April 21, 2026 4:11 PM - SEC Filing
Incyte to present phase 3 tafasitamab data at 2026 ASCO meeting
April 21, 2026 10:00 AM - StreetInsider
Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
April 21, 2026 10:00 AM - BizWire
Form 4 INCYTE CORP For: Apr 15 Filed by: Meury William
April 17, 2026 4:13 PM - SEC Filing
Form 4 INCYTE CORP For: Apr 15 Filed by: CAGNONI PABLO J
April 17, 2026 4:13 PM - SEC Filing
Form 4 INCYTE CORP For: Apr 15 Filed by: Stein Steven H
April 17, 2026 4:13 PM - SEC Filing
Form 144 INCYTE CORP Filed by: CAGNONI PABLO J
April 17, 2026 4:08 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
April 15, 2026 7:18 AM - StreetInsider
Incyte to Report First Quarter Financial Results
April 9, 2026 8:00 AM - BizWire
Palvella Therapeutics names Kent Taylor sales chief
April 7, 2026 12:26 PM - StreetInsider
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
April 7, 2026 12:26 PM - Globe NewsWire
Incyte (INCY) PT Raised to $95 at RBC Capital
April 7, 2026 9:02 AM - StreetInsider
Form 4 INCYTE CORP For: Mar 31 Filed by: HARRIGAN EDMUND
April 2, 2026 4:10 PM - SEC Filing
Form 4 INCYTE CORP For: Mar 31 Filed by: Baker Brothers Life Sciences LP
April 2, 2026 4:10 PM - SEC Filing
Form 4 INCYTE CORP For: Mar 31 Filed by: Clancy Paul J
April 2, 2026 4:10 PM - SEC Filing
Adagene partners with Incyte for cancer drug combination study
April 2, 2026 7:01 AM - StreetInsider
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable
April 2, 2026 7:01 AM - StreetInsider
Incyte (INCY) Reiterated at Market Perform by Citizens- 'Shares are Fairly Valued'
April 2, 2026 5:07 AM - StreetInsider
Form 8-K INCYTE CORP For: Mar 26
March 30, 2026 5:44 PM - SEC Filing
William Blair on Incyte (INCY): 'encouraged' by Ph3 data and deepened responses
March 30, 2026 10:19 AM - StreetInsider
Incyte (INCY) Reiterated at Buy by Stifel on Constructive View for Povorcitinib
March 30, 2026 7:42 AM - StreetInsider
Incyte reports 54-week data for hidradenitis suppurativa drug
March 30, 2026 4:21 AM - StreetInsider
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting
March 28, 2026 3:00 PM - BizWire
Form SCHEDULE 13G/A INCYTE CORP Filed by: VANGUARD GROUP INC
March 27, 2026 9:54 AM - SEC Filing
Form 4 INCYTE CORP For: Mar 25 Filed by: Trotta Matteo
March 26, 2026 4:14 PM - SEC Filing
Form 8-K INCYTE CORP For: Mar 25
March 26, 2026 8:40 AM - SEC Filing
Incyte (INCY) PT Lowered to $94 at UBS
March 25, 2026 9:05 AM - StreetInsider
Incyte names three executives to expanded leadership roles
March 25, 2026 9:01 AM - StreetInsider
Incyte Announces Executive Leadership Appointments
March 25, 2026 9:00 AM - BizWire
H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
March 25, 2026 6:57 AM - StreetInsider
Barclays reiterates Overweight on Incyte (INCY) despite mixed Ph3 trial results
March 24, 2026 4:02 PM - StreetInsider
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting
March 20, 2026 10:00 AM - BizWire
Form 4 INCYTE CORP For: Mar 17 Filed by: CAGNONI PABLO J
March 19, 2026 4:21 PM - SEC Filing
Form 144 INCYTE CORP Filed by: CAGNONI PABLO J
March 17, 2026 4:07 PM - SEC Filing
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico
March 17, 2026 7:31 AM - Globe NewsWire
Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil
March 17, 2026 7:31 AM - Globe NewsWire
Jefferies Downgrades Incyte (INCY) to Hold
March 16, 2026 12:51 AM - StreetInsider
Incyte (INCY) Reiterated at Buy by Stifel After FDA Response to sBLA Submission
March 9, 2026 8:00 AM - StreetInsider
Full Article List
